Simvastatin, a drug with immune-modulatory effect.

Phase 2

Conditions: Plaque psoriasis.
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. Psoriatic lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region
the patholog

Registration Number: IRCT2013122015334N2

Lead Sponsor: Vice chancellor for research, Shiraz University of Medical Sciences.

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 15

Inclusion Criteria

patients arriving at dermatology clinic at Faghihi hospital, with age between 18 and 50years; with diagnosis of chronic plaque psoriasis on extensors surfaces of elbow or knee; Each patient must have at least two symmetric lesions; patient must fill out the inform consent form; Patient must have a negative history of treatment for at least 6 months; Patient must not have chronic debilitating disease.
Exclusion criteria: If patient develops reaction to the drug; if he/she is unwilling to continue the treatment; If the plaque is infected during or before treatment.

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Scaling. Timepoint: 0, 2nd, 4th week. Method of measurement: The photos will be compared by two dermatologist who are unaware of type of medication for each lesion.;Erythema. Timepoint: 0, 2nd, 4th week. Method of measurement: The photos will be compared by two dermatologist who are unaware of type of medication for each lesion.;Area. Timepoint: 0, 2nd, 4th week. Method of measurement: The surface area of th lesions will be calculated by two dermatologists by using photos of the lesions. None of the dermatologists know the treatment used for each lesion.

Secondary Outcome Measures